Cangrelor Improves Heart Recovery in Cardiogenic Shock
A randomized trial found the intravenous blood thinner outperformed oral ticagrelor in heart attack patients with cardiogenic shock.
Updated on Nov. 9, 2026 in Heart Disease

Cangrelor, an intravenous blood thinner, improved heart function recovery in heart attack patients with cardiogenic shock compared to oral ticagrelor. The study randomized 605 patients undergoing cardiac stent procedures.
Why it matters
Cardiogenic shock after a heart attack is fatal within a year in about half of patients, and no therapies beyond prompt revascularization or mechanical heart pumps have been shown effective. The results point to a possible new treatment approach for a condition with few options.
The trial randomized 605 patients, with 298 receiving cangrelor and 307 receiving crushed ticagrelor before stent procedures. Cangrelor achieved the platelet reactivity benchmark in 100 percent of patients versus 22 percent with ticagrelor, while long-term outcomes beyond one year remain under follow-up.
The players
Lancet
The Lancet is a long-established peer-reviewed medical journal that published the DAPT-SHOCK-AMI trial results.
Cangrelor
Cangrelor is an intravenous antiplatelet drug that works by rapidly blocking platelet activation, and it is being evaluated as an alternative to oral blood thinners.
The details
Researchers randomized patients who underwent cardiac stent procedures to receive either cangrelor or crushed ticagrelor before the procedures. The primary laboratory endpoint measured platelet reactivity index to assess how well each drug stopped blood from clotting.
Timeline
Patients were given cangrelor or crushed ticagrelor before their stent procedures.
After one year, cangrelor patients showed greater improvement in heart pumping ability.
The study was published in The Lancet in 2026.
Health Landscape
For cardiogenic shock, the only previously effective options have been prompt revascularization and mechanical heart pumps, leaving drug therapy largely unproven. This first randomized trial of double antiplatelet therapy in heart attacks complicated by cardiogenic shock marks a shift toward medication-based approaches.
Patients who survive cardiogenic shock after a heart attack face a significant risk of heart failure, so improved heart function recovery could affect long-term quality of life. Cangrelor is administered intravenously, a delivery method that differs from the oral ticagrelor used in the comparison group.
The takeaway
A drug delivered before stenting improved heart recovery where few therapies have worked, suggesting that antiplatelet strategy may matter in the most severe heart attacks. Larger trials will be needed to confirm whether these early gains hold over time.
Further reading
Explore more on Heart Disease and how new treatments are changing outcomes for patients with serious cardiac conditions.
More information
Read the full Lancet DAPT-SHOCK-AMI trial abstract00976-1/abstract) for complete study details.







